# Interim report January – March 2023

Moberg Pharma AB (Publ)

**Q1**

Q2

Q3

Q4



# REGISTRATION PROCESS ONGOING, 120-DAY REPORT AND 145-DAY QUESTIONS RECEIVED

*"We remain fully focused on our two most important activities: the registration process for MOB-015 in Europe and patient enrollment in the North American Phase 3 study. Both the registration process and the clinical study are progressing as planned,"* says Anna Ljung, CEO of Moberg Pharma.

## FIRST QUARTER (JAN-MAR 2023)

- EBITDA SEK -6.1 million (-4.8)
- Operating profit (EBIT) SEK -6.7 million (-5.4)
- Profit after tax SEK -5.0 million (-4.4)
- Total profit SEK -5.0 million (-4.4)
- Diluted earnings per share SEK -0.05 (-0.10)
- Cash and cash equivalents amounted to SEK 84.5 million (73.4)

## SIGNIFICANT EVENTS IN THE FIRST QUARTER

- The company regains full rights to MOB-015 in Japan
- The management team is strengthened with the addition of Jesper Lind, Head of Supply.

## SIGNIFICANT EVENTS AFTER THE QUARTER

- The North American study is progressing as planned and all patients are expected to be enrolled by the end of the year
- Progress according to plan with regulatory interactions in the EU, 120-day report and subsequent 145-day questions received
- The Nomination Committee proposes Håkan Wallin as a new member of the Board of Directors

# STATEMENT FROM THE CEO

**We remain fully focused on our two most important activities: the registration process for the nail fungus treatment MOB-015 in Europe and patient enrollment in the North American Phase 3 study. Both the registration process and the clinical study are progressing as planned with key value-creating milestones in 2023.**

The registration process in Europe is now in an intensive phase. We have received the 120-day report and subsequent 145-day questions. Moberg Pharma has submitted a full registration application through the decentralized process, which offers the possibility of data exclusivity in Europe for up to 10 years following market approval. Our goal is to receive the first market approval in 2023.

Together with our partners, we are fully focused on the registration process and are working diligently to formulate the best possible responses to questions from the regulatory authorities. It is a strength for a small company like Moberg Pharma to collaborate with experienced distributors and partners who know their local markets. In total, we have five partnerships in place, including for the EU and Canada. During the quarter, Moberg Pharma regained full rights to MOB-015 in Japan, while the company retains paid milestone revenues of EUR 5 million. This was after our partner conducted an extensive strategic review of its R&D pipeline and decided that the program no longer aligns with its business strategy. This enables potentially new partnerships in Japan going forward.

In March, the American Academy of Dermatology (AAD) held its annual meeting in New Orleans, where we took part and met a majority of the physicians involved in the ongoing North American Phase 3 study. We had many inspiring discussions that underscore the great medical need for a product with MOB-015's profile as well as the enthusiasm of the physicians for the clinical study. In total, more than 30 clinics in the U.S. and Canada are admitting nail fungus patients. The study is progressing as planned and we expect to complete patient enrollment during the year. Since the patients are evaluated over 52 weeks and it takes time to culture fungal samples from the last patient's last visit, we expect to be able to present topline data 15 months after the last patient is enrolled, in Q1 2025. The study will include a total of 350 patients with nail fungus. The study design builds on the experience gained from the previous Phase 3 studies and Moberg Pharma is cooperating with the same CRO, same lead investigator and high-performance clinics from the previous North American study.

We continue to take important steps towards the commercial phase and are advancing towards the company's goal to create the future market leader in the treatment of nail fungus. I look forward with confidence to the first approval, which is expected later this year.

Anna Ljung, CEO of Moberg Pharma

# ABOUT MOBERG PHARMA AND MOB-015

**Moberg Pharma's goal is to make MOB-015 the world's leading treatment for nail fungus and to build a specialty pharmaceutical company with its own sales in the U.S. and sales through partners in other markets. With MOB-015 as an anchor, the company intends to expand the product portfolio with additional products in adjacent areas either developed in-house or acquired.**

MOB-015 is a next-generation treatment for onychomycosis (nail fungus) and the high antifungal effect shown in clinical Phase 3 studies with more than 800 patients indicates that the product has the potential to become the future market leader in nail fungus. Moberg Pharma has signed license agreements with partners in Europe, Canada, Israel and the Republic of Korea for MOB-015. The annual sales potential for MOB-015 is estimated at USD 250–500 million




## SIGNIFICANT MEDICAL NEED – MORE THAN 100 MILLION PATIENTS IN THE EU AND U.S. HAVE NAIL FUNGUS

Despite that one out of every ten people suffers from nail fungus, there currently aren't any good treatment alternatives available. The most effective treatment is oral terbinafine, which is associated with the risk of liver damage and interaction with other drugs. Dermatologists around the world agree on the great need for better topical treatments without the risk of systemic side effects. In a survey in the U.S., 72% of responding physicians avoid prescribing oral terbinafine due to their patients' concern about side effects, and 62% would prefer a product with MOB-015's intended target profile to current topical treatments. Only 6-15% of responding physicians would continue to prescribe current topical treatments. [1]

[1] Survey of 89 U.S. physicians (dermatologists and podiatrists), LifeSci Physician Survey, April 4, 2017

## RESULTS FROM THE TWO PHASE 3 STUDIES SHOW THAT MOB-015 HAS UNIQUE ANTIFUNGAL EFFECT

In December 2019, the results were presented from the first of two clinical studies in the Phase 3 program for MOB-015, followed by the results of the European study in June 2020. Both studies met the primary endpoint. Mycological cure (eradicating the fungal infection) was achieved in 76 percent of the patients (70 percent of the patients in the North American study and 84 percent of the patients in the European study), which is substantially higher than reported for other topical treatments (30-54 percent). Furthermore, the onset of the antifungal effect is more rapid than for oral terbinafine, with MOB-015 delivering 55–78 percent mycological cure at 6 months (vs 40 percent for oral terbinafine) and 37–46 percent already at 3 months (vs 15 percent for oral terbinafine).

MOB-015 is the first topical treatment with a mycological cure rate at the same level as oral terbinafine, the current gold standard for treatment of onychomycosis. Before the recently completed clinical Phase 3 studies with MOB-015, it appeared unrealistic that a topical treatment would achieve a mycological cure rate of 70 percent. Furthermore, the concentration of terbinafine has been shown to be 1000X higher in the nail, 40x higher in the nail bed and 1000X lower in plasma compared to oral terbinafine – ideal characteristics for an effective tropical treatment without systemic exposure.

## FIRST MARKET APPROVAL EXPECTED IN 2023

In March 2022, Moberg Pharma submitted the registration application for MOB-015 to the Medical Products Agency in Sweden, which has agreed to be reference member state for the application. The company has submitted the registration application in Europe through the decentralized process, and market approval is expected in 2023. Moberg Pharma has submitted a full application, which offers the possibility of data exclusivity in Europe for up to 10 years following market approval. The company's goal is to receive its first market approval in 2023.

## NORTH AMERICAN PHASE 3 STUDY UNDERWAY

For market approval in the U.S., the FDA normally requires two studies that demonstrate superiority (statistically superior to the comparator) for the primary endpoint. An additional North American study is now being implemented to enable registration in the U.S. market. Moberg Pharma submitted documentation on the new study to the FDA in March 2022 and the first patient was enrolled in May 2022 and we expect to complete patient enrollment during the year. The randomized, vehicle-controlled, multicenter Phase 3 study will include a total of 350 patients in North America. The patients will be evaluated over 52 weeks and the primary endpoint will be the proportion of subjects achieving complete cure of their target nail. The study design builds on the experience gained from the previous Phase 3 studies and Moberg Pharma is cooperating with the same CRO, same lead investigator and high-performance clinics from the previous North American study. The purpose of the new study is to facilitate market approval in the U.S. as well as strengthen the product's clinical evidence and marketing claims globally.

## AGREEMENTS WITH STRONG PARTNERS IN PLACE – U.S. RIGHTS RETAINED

In total, five agreements are in place with commercial partners for MOB-015: with Cipher Pharmaceuticals for Canada; DongKoo, the market leader in dermatology in the Republic of Korea; Allderma in Scandinavia; Padagis in Israel; and the Consumer Health division of Bayer AG, a world leader in OTC fungus treatments with the brand Canesten, for Europe.

The agreements give these partners exclusive rights to market and sell MOB-015 in each respective market, while Moberg Pharma assumes production and supply responsibility. Within the framework of the agreements Moberg Pharma can receive milestone payments of up to a total USD 70 million upon successful development and commercialization, in addition to royalties and compensation for delivered products.

Previously, Moberg Pharma has successfully commercialized products in the U.S. and therefore has retained the rights to MOB-015 for the U.S. market. The aim is to repeat the journey taken with Kerasal Nail®, where Moberg Pharma combined direct sales in the U.S. with strategic collaborations in other major territories. The most important markets for MOB-015 are expected to be the U.S., EU, Japan, Canada and China, all with patent protection until 2032. In addition to granted patents, the company also has ongoing patent applications which, if approved, could provide significantly longer patent protection.

## PROVEN COMMERCIAL MODEL

Moberg Pharma commercialized its first-generation nail fungus product – Kerasal Nail® - and built an OTC business with annual revenue of SEK 440 million, a 30% market share in the U.S. and more than 30,000 sales locations, including the major chains CVS, Walgreens and Walmart. In 2019, the OTC business was successfully divested for SEK 1.4 billion. The company's aim is now to repeat this journey with MOB-015, a product with much greater potential.

## COMPANY EVENTS

The management team was expanded to include Jesper Lind, Head of Supply, from January 1. He has 35 years of life science experience, of which 30 years is global experience from the pharmaceutical industry in production, supply, supply chain, procurement, external sourcing, new product introduction and pharmaceutical development, from companies such as Orexo, AstraZeneca, Astra, and Pharmacia.

In April, the Nomination Committee presented its proposal for the Board of Directors for the coming year. The Nomination Committee proposes the re-election of Board members Nikolaj Sörensen, Kerstin Valinder Strinnholm and Anders Lundmark, and the election of Håkan Wallin as a new Board member and representative of the company's main shareholder, Östersjöstiftelsen. After serving 9 years on the Board, Mattias Klintemar has announced that he is not available for re-election.

Håkan Wallin has many years of both operative and financial experience from advisory positions as well as from board and management positions in both listed and non-listed life science companies. Previous positions include responsible partner on the corporate finance side for the life science sector at ABG Sundal Collier, EVP Corporate Development at Medivir and Chairman of the Board of Palette Life Sciences (previously PharmanestAB). Håkan is today CFO at NP3 Fastigheter AB.

# FINANCIAL OVERVIEW

## REVENUES AND PROFIT

**First quarter (January - March 2023)**

Pharma's operations consist of research and development, business development and administrative functions. The majority of the development expenditure incurred is directly attributable to the development project MOB-015 and is capitalized. The largest expense items in the quarter therefore consist of business development and administration expenses of SEK 5.4 million (4.9), followed by research and development expenses of SEK 0.8 million (0.6). Other operating income mainly relates to invoiced expenses. Other operating expenses consist of currency adjustments.

## CASH FLOW

**First quarter (January - March 2023)**

Cash flow from operating activities was SEK -5.9 million (-6.0) in the quarter. Cash flow from investments was SEK -34.5 million (-22.5) and relates to capitalized expenditure for the North American Phase 3 study. Cash flow from financing activities was SEK 0.6 million (-0.7) and relates to payments of leasing assets. The total change in cash and cash equivalents in the quarter was SEK -41.0 million (-29.2). Cash and cash equivalents amounted to SEK 84.5 million (73.4) at the end of the period.

## INVESTMENTS

Investments in intangible assets relate to capitalized expenses for development work on MOB-015, mainly the ongoing North American Phase 3 study, of SEK 34.5 million (22.5) in the quarter.

| R&D expenses (costs and investments) (SEK thousand) | Jan-Mar 2023 | Jan-Mar 2022 | Jan-Dec 2022 |
|---|---|---|---|
| **R&D expenses (in statement of comprehensive income)** | **-818** | **-585** | **-1,177** |
| Capitalized R&D investments | -34,498 | -22,520 | -68,072 |
| Depreciation/amortization booked to R&D expenses | 223 | 384 | 1,683 |
| **Change in R&D investments (in statement of financial position)** | **-34,275** | **-22,136** | **-66,389** |
| **Total R&D expenditure** | **-35,093** | **-22,721** | **-67,566** |

### LIABILITIES

As at the balance sheet date, the Group has no interest-bearing liabilities (excluding leasing liabilities).

# CHANGES IN EQUITY

### SHARES

No changes were made to share capital in the quarter. Share capital at the end of the period was SEK 10,085,933.50, where the total number of shares outstanding was 100,859,335 ordinary shares with a quotient value of SEK 0.10. Moberg Pharma holds 2,589,746 repurchased ordinary shares at the end of the period.

### SHARE-BASED COMPENSATION PLANS

As at the reporting date, the number of outstanding instruments was 1,878,100 performance share units, with a maximum potential dilution of 4.4%. Performance share units are issued and held in trust, where the actual number of shares that can be transferred varies depending on the share's performance and whether the company meets its business goals over several years. For detailed information on the incentive programs, see the 2022 Annual Report.

### SHAREHOLDER INFORMATION

The company's largest shareholders per March 31, 2023:

| Shareholder | Number of shares | % of votes and capital |
|---|---|---|
| ÖSTERSJÖSTIFTELSEN | 10,028,503 | 9.9 |
| AVANZA PENSION | 8,195,386 | 8.1 |
| ABN AMRO GLOBAL CUSTODY SERVICES NV, W8IMY | 5,768,696 | 5.7 |
| NORDNET PENSIONSFÖRSÄKRING AB | 3,443,794 | 3.4 |
| MOBERG PHARMA AB (PUBL) | 2,589,746 | 2.6 |
| IBKR FINANCIAL SERVICES AG, W8IMY | 1,616,078 | 1.6 |
| BANQUE CANTONALE VAUDOISE, W8IMY | 1,612,800 | 1.6 |
| KJELSMARK HOLDING APS | 1,601,002 | 1.6 |
| GUNNARSSON, MIKAEL | 1,523,592 | 1.5 |
| ASBERG, FREDRIK ERIK | 1,306,875 | 1.3 |
| CLEARSTREAM BANKING S.A., W8IMY | 1,016,666 | 1.0 |
| LUNDMARK, SVEN ANDERS | 1,001,561 | 1.0 |
| IVELAND, BEATRICE | 1,000,000 | 1.0 |
| OLELIND, ÖRJAN | 1,000,000 | 1.0 |
| ÖHRN, MARTIN LENNART | 918,099 | 0.9 |
| SWEDBANK FÖRSÄKRING | 907,882 | 0.9 |
| LUNDBERG, GÖRAN | 855,336 | 0.9 |
| NORDEA LIVFÖRSÄKRING SVERIGE AB | 803,150 | 0.8 |
| JS ERHVERVS CONSULT APS | 662,323 | 0.7 |
| PLAIN CAPITAL BRONX | 615,000 | 0.6 |
| TOTAL, 20 LARGEST SHAREHOLDERS | 46,466,489 | 46.1 |
| OTHER SHAREHOLDERS | 54,392,846 | 53.9 |
| TOTAL | 100,859,335 | 100 |

# PARENT COMPANY

Moberg Pharma AB (publ), corp. reg. no. 556697-7426, is the parent company of the Group. The operations of the Group are primarily conducted in the parent company and consist of research and development, business development and administrative functions. For the period January to March 2023, the parent company's operating profit was SEK -6.4 million (-5.4), while profit after financial items was SEK -6.5 million (-5.4). Cash and cash equivalents amounted to SEK 84.5 million (73.4) at the end of the period.

# OTHER INFORMATION

## ORGANIZATION

Per March 31, 2023, Moberg Pharma had 9 employees, of whom 89% were women. All were employees of the parent company.

## RISK FACTORS

Commercialization and development of pharmaceuticals are capital-intensive activities exposed to significant risks. Risk factors considered to be of particular significance for Moberg Pharma's future development are linked to the results of clinical trials, regulatory actions, patents and trademarks, key personnel, sensitivity to economic fluctuations, future capital requirements, and financial risk factors. A description of these risks can be found in the company's 2022 Annual Report on page 21.

## OUTLOOK

Moberg Pharma's goal is to create value and provide attractive shareholder returns through the successful commercialization of its pipeline assets.

In the near term, the focus is on registration preparations for MOB-015 in Europe, where a registration application was submitted to the Medical Products Agency in Sweden in March 2022. The company's goal is to receive its first market approval in 2023. Moberg Pharma is also conducting a new North American Phase 3 study, where patient enrollment is expected to be completed in 2023. In parallel with the registration preparations, commercialization preparations are underway to maximize value and create future growth.

## CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

| (SEK thousand) | Jan-Mar 2022 | Jan-Mar 2021 | Jan-Dec 2022 |
|---|---|---|---|
| **Continuing operations** | | | |
| Net revenue | - | - | - |
| Cost of goods sold | - | - | - |
| **Gross profit** | **-** | **-** | **-** |
| | | | |
| Selling expenses | -361 | -125 | -1,014 |
| Business development and administrative expenses | -5,414 | -4,899 | -20,057 |
| Research and development costs | -818 | -585 | -1,177 |
| Other operating income | 207 | 188 | 1,815 |
| Other operating expenses | -287 | - | - |
| **Operating profit (EBIT)** | **-6,673** | **-5,421** | **-20,226** |
| | | | |
| Interest income and similar items | 623 | - | 786 |
| Interest expenses and similar items | -73 | -23 | -72 |
| **Profit after financial items from continuing operations (EBT)** | **-6,123** | **-5,444** | **-19,512** |
| | | | |
| Tax on profit for the period | 1,093 | 1,002 | 3,802 |
| **PROFIT FOR THE PERIOD** | **-5,030** | **-4,442** | **-15,710** |
| | | | |
| **TOTAL PROFIT FOR THE PERIOD** | **-5,030** | **-4,442** | **-15,710** |
| | | | |
| Profit for the period attributable to parent company shareholders | -5,030 | -4,442 | -15,710 |
| Total profit attributable to parent company shareholders | -5,030 | -4,442 | -15,710 |
| **Basic earnings per share** | **-0.05** | **-0.10** | **-0.21** |
| **Diluted earnings per share** [2] | **-0.05** | **-0.10** | **-0.21** |
| | | | |
| **EBITDA FROM CONTINUING OPERATIONS** | **-6,060** | **-4,776** | **-17,644** |
| Depreciation/amortization | -613 | -645 | -2,582 |
| **Operating profit (EBIT)** | **-6,673** | **-5,421** | **-20,226** |

[2] In periods when the Group reports a loss, no dilution effect arises. A dilution effect is only recognized when a potential conversion to ordinary shares would result in lower earnings per share.

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION IN BRIEF

| (SEK thousand) | 2023-03-31 | 2022-03-31 | 2022-12-31 |
|---|---|---|---|
| **Assets** | | | |
| Intangible assets | 435,015 | 349,562 | 408,104 |
| *Capitalized development* [3] | 435,015 | 349,562 | 408,104 |
| **Tangible non-current assets** | 0 | 0 | 0 |
| Right-of-use assets | 5,371 | 3,874 | 5,984 |
| Deferred tax asset | 23,668 | 15,680 | 22,575 |
| **Total non-current assets** | **464,054** | **369,116** | **436,663** |
| Trade receivables and other receivables | 2,702 | 9,206 | 2,210 |
| Cash and cash equivalents | 84,540 | 73,440 | 125,550 |
| **Total current assets** | **87,242** | **82,646** | **127,760** |
| **TOTAL ASSETS** | **551,296** | **451,762** | **564,423** |
| **Equity and liabilities** | | | |
| Equity attributable to parent company's shareholders | 529,079 | 437,709 | 533,584 |
| **Total equity** | **529,079** | **437,709** | **533,584** |
| Non-current leasing liabilities | 3,121 | 544 | 3,988 |
| Non-current non-interest-bearing liabilities | 65 | 65 | 65 |
| **Total non-current liabilities** | **3,186** | **609** | **4,053** |
| Current leasing liabilities | 1,742 | 2,709 | 2,117 |
| Current non-interest-bearing liabilities | 17,289 | 10,735 | 24,669 |
| **Total current liabilities** | **19,031** | **13,444** | **26,786** |
| **TOTAL EQUITY AND LIABILITIES** | **551,296** | **451,762** | **564,423** |

[3] For further details, see note 2.

## CONSOLIDATED STATEMENT OF CASH FLOWS IN BRIEF

| (SEK thousand) | Jan-Mar 2023 | Jan-Mar 2022 | Jan-Dec 2022 |
|---|---|---|---|
| **Operating activities** | | | |
| Operating profit before financial items | -6,673 | -5,421 | -20,226 |
| Financial items, received and paid | -73 | -23 | 717 |
| Taxes paid | - | - | - |
| *Adjustments:* | | | |
| Depreciation/amortization and capital gains | 613 | 645 | 2,582 |
| Employee share-based adjustments to equity [4] | 525 | 552 | 1,458 |
| **Cash flow before changes in working capital** | **-5,608** | **-4,247** | **-15,469** |
| **Change in working capital** | | | |
| Increase (-)/Decrease (+) in operating receivables | -492 | 336 | -210 |
| Increase (+)/Decrease (-) in operating liabilities | 207 | -2,106 | -1,163 |
| **OPERATING CASH FLOW** | **-5,893** | **-6,017** | **-16,842** |
| **Investing activities** | | | |
| Net investments in intangible assets | -34,498 | -22,520 | -68,072 |
| **CASH FLOW FROM INVESTING ACTIVITIES** | **-34,498** | **-22,520** | **-68,072** |
| **Financing activities** | | | |
| Repayment of leases | -619 | -678 | -1,873 |
| Issue of new shares less transaction costs | - | - | 109,682 |
| **CASH FLOW FROM FINANCING ACTIVITIES** | **-619** | **-678** | **107,809** |
| **Change in cash and cash equivalents** | **-41,010** | **-29,215** | **22,895** |
| Cash and cash equivalents at the beginning of period | 125,550 | 102,655 | 102,655 |
| Cash and cash equivalents at the end of period | 84,540 | 73,440 | 125,550 |

[4] Note that revaluation of estimated costs for social security contributions for employee stock options is recognized in change in operating liabilities.

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

| (SEK thousand) | Share capital | Other capital contributions | Accumulated profit/loss | Total equity |
|---|---|---|---|---|
| January 1 – March 31, 2023 | | | | |
| **Opening balance, January 1, 2023** | **9,827** | **841,197** | **-317,440** | **533,584** |
| *Total profit* | | | | |
| Profit for the period | | | -5,030 | -5,030 |
| *Transactions with shareholders* | | | | |
| Share-based incentive program | | 525 | | 525 |
| **CLOSING BALANCE, MARCH 31, 2023** | **9,827** | **841,680** | **-322,923** | **529,079** |

| (SEK thousand) | Share capital | Other capital contributions | Accumulated profit/loss | Total equity |
|---|---|---|---|---|
| January 1 – December 31, 2022 | | | | |
| **Opening balance, January 1, 2022** | **4,405** | **731,376** | **-301,730** | **434,051** |
| *Total profit* | | | | |
| Profit for the period | | | -15,710 | -15,710 |
| *Transactions with shareholders* | | | | |
| New shares issued | 5,422 | 124,168 | | 129,590 |
| Transaction costs | | -15,805 | | -15,805 |
| Share-based incentive program | | 1,458 | | 1,458 |
| **CLOSING BALANCE, DECEMBER 31, 2022** | **9,827** | **841,197** | **-317,440** | **533,584** |

## KEY RATIOS FOR THE GROUP

| (SEK thousand) | Jan-Mar 2023 | Jan-Mar 2022 | Jan-Dec 2022 |
|---|---|---|---|
| Net revenue * | - | - | 207 |
| EBITDA * | -6,060 | -4,776 | -17,644 |
| Operating profit (EBIT) * | -6,673 | -5,421 | -20,226 |
| Total profit | -5,030 | -4,442 | -15,710 |
| Cash and cash equivalents | 84,540 | 73,440 | 125,550 |
| Balance sheet total | 551,296 | 451,762 | 564,423 |
| Equity/assets ratio | 96% | 97% | 95% |
| Return on equity | -1% | -1% | -3% |
| Diluted earnings per share, SEK | -0.05 | -0.10 | -0.21 |
| Equity per share, SEK | 5.38 | 9.68 | 5.43 |
| Basic average number of shares | 98,269,589 | 44,059,676 | 75,871,660 |
| Diluted average number of shares | 101,827,362 | 45,151,355 | 77,523,203 |
| Number of shares at the end of the period excluding repurchased own shares | 98,269,589 | 45,216,377 | 98,269,589 |

** continuing operations*

## DEFINITIONS OF KEY RATIOS

Moberg Pharma presents certain financial performance measurements in the interim report that are not defined in accordance with IFRS. In Moberg Pharma's opinion, these performance measurements provide valuable additional information to investors and company management as they enable an evaluation of the company's performance. These financial performance measurements are not always comparable with those used by other companies since not all companies calculate them in the same manner. Accordingly, these financial measurements are not to be regarded as a substitute for the performance measurements defined in accordance with IFRS.

| | |
|---|---|
| **EBITDA** | Operating profit before depreciation/amortization and impairment of intangible assets and property, plant, and equipment |
| **Equity/assets ratio** | Equity at the end of the period in relation to balance sheet total |
| **Return on equity** | Profit for the period divided by closing equity |
| **Earnings per share*** | Profit after tax divided by the diluted average number of shares |
| **Equity per share** | Equity divided by the number of shares outstanding at the end of the period |

** Defined in accordance with IFRS*

## PARENT COMPANY INCOME STATEMENT SUMMARY

| (SEK thousand) | Jan-Mar 2023 | Jan-Mar 2022 | Jan-Dec 2022 |
|---|---|---|---|
| Net revenue | - | - | 207 |
| Cost of goods sold | - | - | - |
| **Gross profit** | **-** | **-** | **207** |
| | | | |
| Selling expenses | -361 | -125 | -1,014 |
| Business development and administrative expenses | -5,414 | -4,899 | -20,057 |
| Research and development costs | -818 | -585 | -1,177 |
| Other operating income | 207 | 188 | 1,815 |
| Other operating expenses | -287 | - | - |
| **Operating profit** | **-6,673** | **-5,421** | **-20,226** |
| | | | |
| Interest income | 623 | - | 786 |
| Interest expenses | -73 | -23 | -72 |
| **Profit after financial items** | **-6,123** | **-5,444** | **-19,512** |
| | | | |
| Tax on profit for the period | 1,093 | 1,002 | 3,802 |
| **PROFIT** | **-5,030** | **-4,442** | **-15,710** |

## PARENT COMPANY BALANCE SHEET SUMMARY

| (SEK thousand) | 2023-03-31 | 2022-03-31 | 2022-12-31 |
|---|---|---|---|
| **Assets** | | | |
| Intangible non-current assets | 435,015 | 349,562 | 408,104 |
| Tangible non-current assets | - | - | - |
| Right-of-use assets | 5,371 | 3,874 | 5,984 |
| Non-current financial assets | 100 | 100 | 100 |
| Deferred tax asset | 23,668 | 15,680 | 22,575 |
| **Total non-current assets** | **464,154** | **369,216** | **436,763** |
| | | | |
| Trade receivables and other receivables | 2,702 | 9,206 | 2,210 |
| Cash and cash equivalents | 84,540 | 73,440 | 125,550 |
| **Total current assets** | **87,242** | **82,646** | **127,760** |
| | | | |
| **TOTAL ASSETS** | **551,396** | **451,862** | **564,523** |
| | | | |
| **Equity and liabilities** | | | |
| Equity | 529,080 | 437,709 | 533,585 |
| | | | |
| Non-current leasing liabilities | 3,121 | 544 | 3,988 |
| Non-current non-interest-bearing liabilities | 65 | 65 | 65 |
| **Total non-current liabilities** | **3,186** | **609** | **4,053** |
| | | | |
| Liabilities to Group companies | 99 | 2,709 | 99 |
| Current leasing liabilities | 1,742 | 99 | 2,117 |
| Current non-interest-bearing liabilities | 17,289 | 10,736 | 24,669 |
| **Total current liabilities** | **19,130** | **13,544** | **26,885** |
| | | | |
| **TOTAL EQUITY AND LIABILITIES** | **551,396** | **451,862** | **564,523** |

## PARENT COMPANY CASH FLOW STATEMENT SUMMARY

| (SEK thousand) | Jan-Mar 2023 | Jan-Mar 2022 | Jan-Dec 2022 |
|---|---|---|---|
| **Operating activities** | | | |
| Operating profit before financial items | -6,673 | -5,421 | -20,226 |
| Financial items, received and paid | -73 | -23 | 717 |
| *Adjustments:* | | | |
| Depreciation/amortization and capital gains | 613 | 645 | 2,582 |
| Expenses for share-based incentive program | 525 | 552 | 1,458 |
| **Cash flow before changes in working capital** | **-5,608** | **-4,247** | **-15,469** |
| | | | |
| **Change in working capital** | | | |
| Increase (-)/Decrease (+) in operating receivables | -492 | 336 | -210 |
| Increase (+)/Decrease (-) in operating liabilities | 207 | -2,106 | -1,163 |
| | | | |
| **OPERATING CASH FLOW** | **-5,893** | **-6,017** | **-16,842** |
| | | | |
| **Investing activities** | | | |
| Net investments in intangible assets | -34,498 | -22,520 | -68,072 |
| **CASH FLOW FROM INVESTING ACTIVITIES** | **-34,498** | **-22,520** | **-68,072** |
| | | | |
| **Financing activities** | | | |
| Repayment of leases | -619 | -678 | -1,873 |
| Issue of new shares less transaction costs | - | - | 109,682 |
| **CASH FLOW FROM FINANCING ACTIVITIES** | **-619** | **-678** | **107,809** |
| | | | |
| **Change in cash and cash equivalents** | **-41,010** | **-29,215** | **22,895** |
| Cash and cash equivalents at the beginning of the period | 125,550 | 102,655 | 102,655 |
| Cash and cash equivalents at the end of the period | 84,540 | 73,440 | 125,550 |

## NOTE 1 ACCOUNTING POLICIES AND MEASUREMENT PRINCIPLES

The interim report was prepared in accordance with IAS 34 and the Swedish Annual Accounts Act. The consolidated financial statements were, like the annual accounts for 2022, prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. The parent company financial statements were prepared in accordance with Swedish Annual Accounts Act and Recommendation RFR 2 of the Swedish Financial Reporting Board, Financial Statements for Legal Entities.

Amounts are presented in Swedish kronor and rounded to the nearest thousand unless otherwise stated. Rounding to the nearest thousand may mean that certain amounts do not match when added up. Amounts and figures in parentheses refer to comparable figures for the corresponding period in 2022.

## NOTE 2 SPECIFICATION OF MAJOR INTANGIBLE NON-CURRENT ASSETS

| (SEK thousand) | 2023-03-31 | 2022-03-31 | 2022-12-31 |
|---|---|---|---|
| Capitalized expenditure for MOB-015 | 435,015 | 349,562 | 408,104 |
| **TOTAL CAPITALIZED EXPENDITURE FOR DEVELOPMENT WORK** | **435,015** | **349,562** | **408,104** |

## NOTE 3 SEGMENT REPORTING

Moberg Pharma's operations comprise only one area of operation: the commercialization and development of medical products. The statement of comprehensive income and statement of financial position as a whole therefore comprise one operating segment.

## NOTE 4 RELATED PARTY TRANSACTIONS

No material changes have occurred in the nature and scope of transactions with related parties compared with disclosures in the Annual Report.

## INFORMATION AND FINANCIAL CALENDAR

This information is such that Moberg Pharma AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation and the Securities Market Act.

| | |
|---|---|
| Interim report for January–June 2023 | August 15, 2023 |
| Interim report for January– September 2023 | November 7, 2023 |

The Annual General Meeting of Moberg Pharma will be held at 4:30 PM on May 16, 2023, in the company's office. The Annual Report is available on the company's website at www.mobergpharma.se

## FOR FURTHER INFORMATION, PLEASE CONTACT

Anna Ljung, CEO, tel. 08-522 307 01, anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, tel. 076 - 805 82 88, mark.beveridge@mobergpharma.se

For more information on Moberg Pharma's business, please see the company's website, www.mobergpharma.com.

The interim report has not been reviewed by the Company's auditors.

## DECLARATION

The undersigned hereby declare that the interim report provides a true and fair overview of the operations, financial position, and results of the parent company and Group, as well as a fair description of significant risks and uncertainties faced by the parent company and Group companies.

Bromma, May 9, 2023

| | | |
|---|---|---|
| Kerstin Valinder Strinnholm<br>*Chairman* | Anders Lundmark<br>*Board member* | Nikolaj Sörensen<br>*Board member* |
| Mattias Klintemar<br>*Board member* | Anna Ljung<br>*CEO* | |